“A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S29. doi:10.25251/skin.2.supp.28.